On April 23, 2026, the US Food and Drug Administration (FDA) authorized Otarmeni (lunsotogene parvec-cwha), the first-ever gene therapy for children and adults suffering from severe-to-profound hearing loss caused by OTOF gene mutations. This landmark approval, processed under the FDA’s new “national priority” voucher program, signals a shift from mechanical hearing aids toward the restoration of 24/7 natural hearing.
The therapy works by using a disarmed viral vector to deliver a functional copy of the OTOF gene directly into the inner ear, allowing the production of a protein essential for transmitting sound signals to the brain. In a pivotal study involving 20 children, 80% of participants achieved moderate-to-normal hearing thresholds within six months of treatment. Clinical data also suggested a broad treatment window, showing consistent efficacy across different age groups, including older adolescents.
Strategically, Regeneron has pledged to provide Otarmeni at no cost to clinically eligible individuals in the United States, although procedural costs for the surgical administration may still apply. While the target population for OTOF-related deafness is relatively small and the competitive landscape is tightening with firms like Eli Lilly developing similar candidates, Otarmeni’s approval remains a major public health milestone, offering a permanent biological fix for a previously untreatable condition.
Source: https://www.biopharmadive.com/news/regeneron-fda-otarmeni-hearing-loss-gene-therapy-voucher/818345/